BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35915022)

  • 41. Epidemiology of triple negative breast cancers.
    Gierach GL; Burke A; Anderson WF
    Breast Dis; 2010; 32(1-2):5-24. PubMed ID: 21965309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A prospective cohort study of clinical characteristics and outcomes in Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer.
    Fan Y; Zhong X; Wang Y; Wang Z; Luo T; Wang Y; Zheng H
    Breast Cancer Res Treat; 2023 Jul; 200(2):171-182. PubMed ID: 37199804
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
    Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
    Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Do clinical features and survival of single hormone receptor positive breast cancers differ from double hormone receptor positive breast cancers?
    Ng CH; Pathy NB; Taib NA; Ho GF; Mun KS; Rhodes A; Looi LM; Yip CH
    Asian Pac J Cancer Prev; 2014; 15(18):7959-64. PubMed ID: 25292095
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic role of progesterone receptor expression in a population-based analysis.
    Caldarella A; Barchielli A
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2505-2509. PubMed ID: 28889189
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
    Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
    Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
    Gulbahce HE; Sweeney C; Surowiecka M; Knapp D; Varghese L; Blair CK
    Hum Pathol; 2013 Nov; 44(11):2427-31. PubMed ID: 23998430
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
    Yu KD; Jiang YZ; Hao S; Shao ZM
    BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival.
    Dauphine C; Moazzez A; Neal JC; Chlebowski RT; Ozao-Choy J
    Ann Surg Oncol; 2020 Nov; 27(12):4687-4694. PubMed ID: 32725527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors for Survival and Distribution of 21-Gene Recurrence Score in Patients With Pure Mucinous Breast Cancer: A SEER Population-Based Retrospective Analysis.
    Ding S; Wu J; Lin C; Chen W; Li Y; Shen K; Zhu L
    Clin Breast Cancer; 2019 Feb; 19(1):e66-e73. PubMed ID: 30396812
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
    Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
    J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas.
    Lal P; Tan LK; Chen B
    Am J Clin Pathol; 2005 Apr; 123(4):541-6. PubMed ID: 15743737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast.
    Paone JF; Abeloff MD; Ettinger DS; Arnold EA; Baker RR
    Surg Gynecol Obstet; 1981 Jan; 152(1):70-4. PubMed ID: 7455895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
    Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
    Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
    Nwafor CC; Keshinro SO
    Niger J Clin Pract; 2015; 18(4):553-8. PubMed ID: 25966732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
    Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
    Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.